KR970706815A - 온단세트론을 포함하는 경구 조성물(Oral Compositions Containing Ondansetron) - Google Patents
온단세트론을 포함하는 경구 조성물(Oral Compositions Containing Ondansetron)Info
- Publication number
- KR970706815A KR970706815A KR1019970703400A KR19970703400A KR970706815A KR 970706815 A KR970706815 A KR 970706815A KR 1019970703400 A KR1019970703400 A KR 1019970703400A KR 19970703400 A KR19970703400 A KR 19970703400A KR 970706815 A KR970706815 A KR 970706815A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- ondansetron
- sweetener
- terms
- polyhydric alcohol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 21
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 title claims abstract 8
- 229960005343 ondansetron Drugs 0.000 title claims abstract 8
- 235000003599 food sweetener Nutrition 0.000 claims abstract 6
- 150000005846 sugar alcohols Polymers 0.000 claims abstract 6
- 239000003765 sweetening agent Substances 0.000 claims abstract 6
- 239000007788 liquid Substances 0.000 claims abstract 2
- 230000001404 mediated effect Effects 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 208000024891 symptom Diseases 0.000 claims abstract 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 2
- 229930091371 Fructose Natural products 0.000 claims 2
- 239000005715 Fructose Substances 0.000 claims 2
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical group O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Dental Preparations (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 온단세트론 또는 약학적으로 허용가능한 그의 유도체, 감미료 및 하나 이상의 약학적으로 허용가능한 부형제를 포함하며 감미료가 하나 이상의 다가 알코올을 포함하고, 조성물의 pH가 2.0 내지 5.0범위인 경구 투여용 액체 조성물에 관한 것이다. 또한 그러한 조성물의 제조 방법, 및 5HT3수용체에서 5-히드록시트 립타민(5HT)의 작용을 통해 매개되는 증상의 치료에서의 사용 방법을 설명한다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (13)
- 온단세트론 또는 제약학적으로 허용가능한 그의 유도체, 감미료 및 하나 이상의 제약학적으로 허용가능한 부형제를 포함하며 감미료가 하나 이상의 다가 알코올을 포함하고, 조성물의 pH가 2.0 내지 5.0범위인 경구투여용 액체 조성물.
- 제1항에 있어서, 염산염 형태의 온단세트론을 포함하는 조성물.
- 제1항에 있어서, 염산염 이수화물 형태의 온단세트론을 포함하는 조성물.
- 제1항 내지 3항 중 어느 한 항에 있어서, 감미료가 소로비톨을 포함하는 조성물.
- 제4항에 있어서, 염산염 이수화물 형태의 온단세트론과 감미료로서 소로비톨을 포함하는 조성물.
- 제1항 내지 5항 중 어느 한 항에 있어서, 조성물 중의 온단세트론의 농도가 유리 염기로 환산하여 0.005 내지 1%w/v 범위인 조성물.
- 제1항 내지 6항 중 어느 한 항에 있어서, 조성물 중의 다가 알코올의 총 함량이 다가 알코올 고체로 환산하여 20 내지 85%w/v 범위인 조성물.
- 제1항 내지 7항 중 어느 한 항에 있어서, pH가 2.5 내지 4.5범위인 조성물.
- 제1항에 내지 8항 중 어느 한 항에 있어서, 조성물 중의 온단세트론의 농도가 유리 염기로 환산하여 0.005 내지 1%w/v 범위이고, 조성물 중의 다가 알코올의 총함량이 다가 알코올 고체로 환산하여 20 내지 85%w/v범위이며, pH가 2.5 내지 4.5범위인 조성물.
- 제1항 내지 9항 중 어느 한 항에 있어서, 점도가 1 내지 100cps 범위인 조성물.
- 제1항 내지 10항 중 어느 한 항에 있어서, 과당 또는 과당 함유 사카라이드를 실절적으로 포함하지 않는 조성물.
- 제1항 내지 11항 중 어느 한 항에 따른 조성물을 투여하는 것을 포함하는, 5HT3, 수용체에서 5HT의 작용을 통해 매개되는 증상을 고통받는 포유류(사람 포함)를 치료하는 방법.
- 제12항에 있어서, 구토증 치료를 위한 방법※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9423588.4 | 1994-11-22 | ||
GB9423588A GB9423588D0 (en) | 1994-11-22 | 1994-11-22 | Compositions |
PCT/IB1995/001152 WO1996015786A2 (en) | 1994-11-22 | 1995-11-20 | Oral compositions containing ondansetron |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970706815A true KR970706815A (ko) | 1997-12-01 |
KR100292124B1 KR100292124B1 (ko) | 2001-07-12 |
Family
ID=10764811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019970703400A KR100292124B1 (ko) | 1994-11-22 | 1995-11-20 | 온단세트론을포함하는경구조성물 |
Country Status (33)
Country | Link |
---|---|
US (1) | US5854270A (ko) |
EP (1) | EP0792149B1 (ko) |
JP (1) | JP2965704B2 (ko) |
KR (1) | KR100292124B1 (ko) |
CN (1) | CN1108153C (ko) |
AT (1) | ATE196084T1 (ko) |
AU (1) | AU703932B2 (ko) |
BE (1) | BE1009458A5 (ko) |
BR (1) | BR9509807A (ko) |
CA (1) | CA2205546C (ko) |
CY (1) | CY2171B1 (ko) |
CZ (1) | CZ285187B6 (ko) |
DE (1) | DE69518767T2 (ko) |
DK (1) | DK0792149T3 (ko) |
ES (1) | ES2151083T3 (ko) |
FI (1) | FI119356B (ko) |
FR (1) | FR2727015B1 (ko) |
GB (2) | GB9423588D0 (ko) |
GR (1) | GR3034684T3 (ko) |
HK (1) | HK1009590A1 (ko) |
HU (1) | HU226947B1 (ko) |
IE (1) | IE950884A1 (ko) |
IL (1) | IL116083A (ko) |
IT (1) | IT1282353B1 (ko) |
NO (1) | NO306892B1 (ko) |
NZ (1) | NZ297879A (ko) |
PL (1) | PL181522B1 (ko) |
PT (1) | PT792149E (ko) |
RU (1) | RU2145853C1 (ko) |
SI (1) | SI0792149T1 (ko) |
TW (1) | TW413634B (ko) |
WO (1) | WO1996015786A2 (ko) |
ZA (1) | ZA959820B (ko) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2162561B1 (es) * | 1999-06-28 | 2002-07-16 | Boehringer Ingelheim Espana | Composicion farmaceutica de metamizol oral, liquida, transparente, estable y de sabor aceptable. |
US6473876B1 (en) | 1999-06-29 | 2002-10-29 | Sony Corporation | Method and apparatus for encoding of bitstreams using rotation |
WO2001013909A2 (en) * | 1999-08-25 | 2001-03-01 | Cooper Barrett R | Compositions and methods for treating opiate intolerance |
CN1498216A (zh) * | 2000-10-30 | 2004-05-19 | ������ҩ��ҵ����˾ | 新的奥丹西隆盐酸盐晶体和溶剂化物及其制备方法 |
US20020115707A1 (en) * | 2001-01-11 | 2002-08-22 | Rami Lidor-Hadas | Process for preparing pure ondansetron hydrochloride dihydrate |
WO2003084518A2 (fr) | 2002-04-09 | 2003-10-16 | Flamel Technologies | Suspension orale de microcapsules de principes actifs |
US7098345B2 (en) * | 2002-04-29 | 2006-08-29 | TEVA Gyógyszergyár Zárkörüen Müködö Részvénytársaság | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one |
CA2483532A1 (en) * | 2002-04-30 | 2003-11-13 | Biogal Gyogyszergyar Rt. | Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them |
US20050131045A1 (en) * | 2002-04-30 | 2005-06-16 | Judith Aronhime | Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them |
AU2003302072A1 (en) * | 2002-11-15 | 2004-06-15 | Helsinn Healthcare Sa | Palonosetron for the treatment of chemotherapy-induced emesis |
JO2735B1 (en) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
US8598219B2 (en) | 2003-01-30 | 2013-12-03 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
MY143789A (en) * | 2003-02-18 | 2011-07-15 | Helsinn Healthcare Sa | Use of palonosetron treating post- operative nausea and vomiting |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
US20060167072A1 (en) * | 2004-01-30 | 2006-07-27 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
JP2006028028A (ja) * | 2004-07-12 | 2006-02-02 | Teikoku Medix Kk | 経口医薬組成物 |
CN100423779C (zh) * | 2006-09-27 | 2008-10-08 | 中国药科大学 | 一种以5-羟色胺3受体拮抗剂和h2受体拮抗剂为活性成分的药用组合物及其制药用途 |
PL2124556T3 (pl) | 2006-10-09 | 2015-02-27 | Charleston Laboratories Inc | Kompozycje farmaceutyczne |
JP5714910B2 (ja) | 2008-01-09 | 2015-05-07 | チャールストン ラボラトリーズ,インコーポレイテッド | 薬学的組成物 |
US20110201597A1 (en) * | 2008-03-27 | 2011-08-18 | Chase Thomas N | Method and composition for treating alzheimer-type dementia |
WO2011006012A1 (en) | 2009-07-08 | 2011-01-13 | Charleston Laboratories Inc. | Pharmaceutical compositions |
EP2478099B1 (en) * | 2009-09-18 | 2019-06-05 | Chase Pharmaceuticals Corporation | Combination for treating alzheimer-type dementia |
US20110288115A1 (en) * | 2010-05-24 | 2011-11-24 | Avmedis Llc | Treatment of vagally-mediated spectrum disorders |
US20120302616A1 (en) * | 2010-12-03 | 2012-11-29 | Nikhilesh Singh | Method of treatment of obsessive compulsive disorder with ondansetron |
KR101058749B1 (ko) * | 2010-12-29 | 2011-08-24 | 에스씨바이오팜 주식회사 | 네오헤스피리딘 디하이드로찰콘을 감미료로 사용하는 온단세트론 염산염 이수화물 함유 액상 조성물 |
JP2015531346A (ja) | 2012-09-05 | 2015-11-02 | チェイス・ファーマスーティカルズ・コーポレーション | 抗コリン作用性神経保護組成物及び方法 |
US10172833B2 (en) | 2015-08-11 | 2019-01-08 | Insys Development Company, Inc. | Sublingual ondansetron spray |
KR101635820B1 (ko) * | 2015-10-30 | 2016-07-04 | 재단법인 통합의료진흥원 | 온단세트론 및 반하후박탕을 포함하는 항암치료 보조용 조성물 |
JP2019507181A (ja) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ,インコーポレイテッド | 医薬組成物 |
KR101721094B1 (ko) * | 2016-09-09 | 2017-03-29 | 재단법인 통합의료진흥원 | 댕댕이나무 열매 추출물을 포함하는 오심 및 구토 치료 효과 증진용 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH664152A5 (fr) * | 1984-01-25 | 1988-02-15 | Glaxo Group Ltd | Derives de tetrahydrocarbazolones. |
JPH0648960A (ja) * | 1990-02-22 | 1994-02-22 | Glaxo Group Ltd | 医 薬 |
ITMI922854A1 (it) * | 1992-12-15 | 1994-06-15 | Boehringer Ingelheim Italia | Uso degli antagonisti dei recettori 5-ht3 |
-
1994
- 1994-11-22 GB GB9423588A patent/GB9423588D0/en active Pending
-
1995
- 1995-11-20 ES ES95941825T patent/ES2151083T3/es not_active Expired - Lifetime
- 1995-11-20 PT PT95941825T patent/PT792149E/pt unknown
- 1995-11-20 PL PL95320288A patent/PL181522B1/pl unknown
- 1995-11-20 CN CN95197225A patent/CN1108153C/zh not_active Expired - Lifetime
- 1995-11-20 EP EP95941825A patent/EP0792149B1/en not_active Expired - Lifetime
- 1995-11-20 DK DK95941825T patent/DK0792149T3/da active
- 1995-11-20 ZA ZA959820A patent/ZA959820B/xx unknown
- 1995-11-20 IT IT95RM000763A patent/IT1282353B1/it active IP Right Grant
- 1995-11-20 WO PCT/IB1995/001152 patent/WO1996015786A2/en active IP Right Grant
- 1995-11-20 CA CA002205546A patent/CA2205546C/en not_active Expired - Lifetime
- 1995-11-20 AT AT95941825T patent/ATE196084T1/de active
- 1995-11-20 NZ NZ297879A patent/NZ297879A/xx not_active IP Right Cessation
- 1995-11-20 DE DE69518767T patent/DE69518767T2/de not_active Expired - Lifetime
- 1995-11-20 FR FR9513722A patent/FR2727015B1/fr not_active Expired - Lifetime
- 1995-11-20 HU HU9800736A patent/HU226947B1/hu unknown
- 1995-11-20 IE IE950884A patent/IE950884A1/en not_active IP Right Cessation
- 1995-11-20 SI SI9530444T patent/SI0792149T1/xx unknown
- 1995-11-20 US US08/817,831 patent/US5854270A/en not_active Expired - Lifetime
- 1995-11-20 RU RU97110066A patent/RU2145853C1/ru active
- 1995-11-20 GB GB9523666A patent/GB2295317B/en not_active Expired - Lifetime
- 1995-11-20 KR KR1019970703400A patent/KR100292124B1/ko not_active IP Right Cessation
- 1995-11-20 JP JP8516719A patent/JP2965704B2/ja not_active Expired - Lifetime
- 1995-11-20 CZ CZ971548A patent/CZ285187B6/cs not_active IP Right Cessation
- 1995-11-20 BR BR9509807A patent/BR9509807A/pt not_active Application Discontinuation
- 1995-11-20 AU AU43135/96A patent/AU703932B2/en not_active Expired
- 1995-11-21 IL IL11608395A patent/IL116083A/xx not_active IP Right Cessation
- 1995-11-21 BE BE9500956A patent/BE1009458A5/fr active
- 1995-12-13 TW TW084113264A patent/TW413634B/zh not_active IP Right Cessation
-
1997
- 1997-05-21 FI FI972168A patent/FI119356B/fi not_active IP Right Cessation
- 1997-05-21 NO NO972324A patent/NO306892B1/no not_active IP Right Cessation
-
1998
- 1998-09-04 HK HK98110451A patent/HK1009590A1/xx not_active IP Right Cessation
-
2000
- 2000-05-23 CY CY0000018A patent/CY2171B1/xx unknown
- 2000-10-26 GR GR20000402371T patent/GR3034684T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR970706815A (ko) | 온단세트론을 포함하는 경구 조성물(Oral Compositions Containing Ondansetron) | |
KR970706814A (ko) | 동결 건조된 온단세트론 조성물(Freeze-Dried Ondansetron Compositions) | |
RU97110066A (ru) | Содержащие ондансетрон составы для перорального введения | |
ATE260646T1 (de) | Schnell zerfallende orale dosierungsform | |
RU2220723C2 (ru) | Средство и способ лечения или профилактики артериосклероза | |
KR960700061A (ko) | 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence) | |
EE03235B1 (et) | Emulsioonvorm, selle valmistamise protsess ja kasutamine | |
ATE311928T1 (de) | (-)-pseudoephedrin als sympathomimetisches arzneimittel | |
KR910002792A (ko) | 1-치환된-2-(3-아미노-1-프로피닐)피롤리딘 유도체, 그에 의한 중추 콜린성 기능 장해 치료 방법 및 그로구성되는 제약학적 조성물 | |
KR910014121A (ko) | 위궤양 및 미란 치료용인 시메티딘-피렌제핀 제제 | |
KR970702054A (ko) | 헬리코박터 파이로리에 기인한 위장 기능장해 치료를 위한 스피라마이신의 용도(use of spiramycin for treating gastrointestinal disorders caused by h. pylori) | |
ES2175086T3 (es) | Composiciones farmaceuticas anti-emeticas que contienen metotrimeprazina. | |
ATE353221T1 (de) | Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa | |
KR970073595A (ko) | 알콜성 장해 예방 및 치료제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130227 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20140227 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20150227 Year of fee payment: 15 |
|
EXPY | Expiration of term |